A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • BRCA1 Protein
  • Germ-Line Mutation
  • Pancreatic Neoplasms

abstract

  • In patients with known BRCA 1 or 2 mutation-associated pancreatic adenocarcinoma, the addition of a DNA cross-linking agent such as cisplatin, oxaliplatin, or mitomycin to a standard gemcitabine chemotherapy backbone should be considered. Poly ADP-ribose inhibitors are a novel class of drug, which have demonstrated promising efficacy in trials of BRCA 1 and 2 mutant breast and ovarian cancer, and are currently undergoing prospective evaluation in advanced pancreatic cancer.

publication date

  • September 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s12029-010-9197-1

PubMed ID

  • 20711688

Additional Document Info

start page

  • 160

end page

  • 4

volume

  • 42

number

  • 3